et al.. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
Current antiviral treatment for CHC has significant side effects and has a far from optimal efficacy, particularly in patients with genotype 1 (3, 4) . Thus, identification of significant liver fibrosis stage is essential to establish the timing of antiviral treatment (5) . Furthermore, the diagnosis of cirrhosis not only establishes the need for antiviral treatment but is crucial for identifying those patients in whom screening for gastroesophageal varices and hepatocellular carcinoma is mandatory. Finally, assessment of the effect of antiviral treatment on liver fibrosis is another desirable end point for evaluation of the efficacy of therapy. Liver biopsy is classically considered the reference standard to assess the extent of fibrosis, though it is associated with risk of complications and has limitations due to observer variability and sampling error (6) (7) (8) . Thus, several routine laboratory tests combined in scores and indices such as Forns'score, APRI index and FIB-4 index, have been developed and validated as useful noninvasive and inexpensive tools to accurately detect significant fibrosis or cirrhosis in clinical practice (9) (10) (11) (12) . Furthermore, a panel of 5 markers (α2-macroglobulin, haptoglobin, apolipoprotein A1, gammaglutamyl transpeptidase and total bilirubin), that is commercialized as FibroTest, has also been validated in the detection of fibrosis and in the evaluation of response to interferon based therapy (13, 14) .
More recently, transient elastography has become a useful, rapid and reproducible novel method to assess liver fibrosis through the measurement of liver stiffness. It has been shown to have good diagnostic performance when combined with FibroTest (15, 16) . The aims of the present study were (1) to validate and compare the diagnostic performance of several noninvasive tests in the prediction of liver fibrosis severity in a large cohort of patients with CHC from a single center, and (2) to assess the relationship between changes in serum ECM markers and virologic response to antiviral therapy. weeks after the end of therapy.
Patients and methods

Patient population
All patients provided written informed consent to data handling according to a protocol approved by the ethical committee of our Institution.
Liver Histology
Percutaneous liver biopsies were performed under local anesthesia and ultrasound guidance with a Tru-Cut 14 gauge needle (Angiomed, Bard, Karlsruhe, Germany) by expert radiologists. Specimens were fixed in formalin, embedded in paraffin and stained with hematoxylin-eosin and Masson´s trichrome. A minimum length of 10 mm and the presence of 6 portal tracts were required for diagnosis. Histological grade and stage were determined according to METAVIR scoring system (27) by the same pathologist (M.B.), who was blinded for patients' data. Liver fibrosis was considered significant when it spread out of the portal tract (stages 2, 3 or 4). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   6 Baseline blood samples were collected on the day of antiviral treatment initiation, as well as at the end of treatment and the end of follow-up on a protocol basis. Laboratory tests included complete blood cell counts, HCV RNA serum concentration, HCV genotype, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT) and cholesterol. These parameters were used to calculate Forns´score, APRI index and FIB-4 index at baseline and at 24 weeks after treatment, as previously described (9) (10) (11) (12) .
Routine laboratory tests
Serum markers of ECM assays
Fasting serum samples (collected at baseline and at 24 weeks after antiviral treatment) were stored at -80 º C until assayed for levels of HA, TIMP-1 and PIIINP. ECM assays were determined using a random access automated clinical immunochemistry analyzer that performs magnetic separation enzyme immunoassay The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), likelihood ratios (LR) and diagnostic odds ratios (DOR) were determined, using hepatic fibrosis stage as determined by liver biopsy as the reference. DOR measures the overall (29) .
Results
Characteristics of patients
Baseline clinical, laboratory and virologic characteristics of the 340 patients are shown in 
Performance of noninvasive tests
The results for the overall accuracy of the different tests for significant fibrosis and cirrhosis are presented as ROC curves in figures 1 and 2, respectively. The AUROCs of Forns´ score, APRI, FIB-4 index and the ELF score had similar diagnostic accuracies for significant For those patients with an ELF score higher than 1.73, 65 of 86 (76%) had cirrhosis. With these thresholds absence or presence of cirrhosis could be correctly identified in 53%, and liver biopsy could be avoided in 63%.
Baseline ECM markers as predictors of virologic response
One hundred and sixty-two patients achieved a sustained virologic response while 178 patients did not. Among the latter, 62 patients had undetectable HCV-RNA at the end of treatment but relapsed during follow-up. Baseline clinical characteristics according to virologic response are shown in Table 4 . Sustained virologic responders were more likely to have lower baseline levels of GGT, glucose, and HCV RNA, higher levels of cholesterol, higher platelet count, non-1 HCV genotype, and less severe fibrosis. The ELF score and two 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Score changes according to virologic response
Among the 340 patients included in this study, 161 had serum samples available for measurement of matrix markers at 24 weeks of follow-up after treatment (limited availability of reagents precluded testing of all samples). Baseline characteristics of this subset of patients are shown in Table 1 . Eighty-five patients achieved sustained virologic response and seventy-six, including 39 who relapsed, did not.
Changes in the mean ELF score and its components are summarized in Table 5 . At 24 weeks after therapy the ELF score decreased significantly in patients who achieved sustained virologic response but remained unchanged in those who did not. The mean ELF score did not change significantly in relapsers (data not shown). A significant decrease of all of the components of the ELF score was observed in sustained virologic responders whereas HA and PIIINP remained unchanged and TIMP-1 increased in non sustained responders.
The individual changes in the ELF score according to virologic response and to the severity of liver fibrosis at baseline are shown in Figure 3 . On an individual basis, the ELF score decreased in most sustained virologic responders but in only a minority of non sustained virologic responders, in most of whom the ELF score remained unchanged or increased. The decrease of the ELF score was more marked in patients with more advanced liver fibrosis, who showed higher mean ELF scores at baseline.
As expected, Forns´score, APRI and FIB-4 index decreased significantly in patients who achieved sustained virologic response (Table 5) . This is mainly due to the normalization of their respective components (particularly AST and ALT).
Discussion
The use of routine hematological and biochemical parameters combined in panels such as Forns´ score, APRI or FIB-4 index, is an "indirect", easy and inexpensive approach to identify patients with significant fibrosis and cirrhosis. The Forns´ score was developed and validated in a population where only 25% of patients had significant hepatic fibrosis (9) while the prevalence of significant fibrosis in the present cohort was much higher (67 %).
This difference may explain why this test performed better in the present cohort than in the original study to rule in significant fibrosis, with a PPV higher than 90%, but not to exclude significant fibrosis. Similarly, the PPV for significant fibrosis obtained in this study with APRI ≥ 1.5, compared favorably with that reported in the original study (93% vs. 88%),
although the NPV at the 0. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The main purpose of this study, was to assess the performance of a score based on fibrogenesis markers (ELF score), due to its potential utility to evaluate changes during follow-up or after treatment. The testing algorithm is patented but is not yet commercially available in most countries. In our cohort, the ELF score yielded a good accuracy in the diagnosis of liver fibrosis and cirrhosis, with similar accuracy to that of simple panels. Moreover, our study showed a significant decrease of the mean serum concentration of ECM markers in patients who had eliminated the virus, which did not occur in non responders or in relapsers. As expected, analysis of the combined ELF score produced similar results. Analysis of changes in individual patients showed that the ELF score decreased in most sustained virologic responders, particularly in those with more severe fibrosis at baseline, whereas the ELF scores increased or remained unchanged in most non- In our study, the significant increase in serum TIMP-1 levels observed at the end of followup in non-sustained virologic responders may indicate that fibrosis is progressing in these patients. Indeed, other reports found a similar TIMP-1 increase following interferon alfa therapy in nonresponder patients (35-37). TIMP-1 protects collagen from fibrolysis by the matrix metalloproteinases and also inhibits the apoptosis of hepatic stellate cells (38). In experimental models, overexpression of TIMP-1 was associated to enhanced fibrosis, supporting the hypothesis that inhibition of matrix degradation may contribute to progression of fibrosis (39).
We also observed significant post-treatment changes of Forns' score, APRI and FIB-4 tests.
However several components of these tests, such as serum cholesterol, platelet counts and particularly transaminases, that are not directly involved in hepatic fibrogenesis or fibrolysis, may change under antiviral therapy, particularly in responders.
Of interest, by multivariate analysis, HA, a component of the ELF score showed an association with sustained virologic response. Previous studies have shown that HA levels reflect an increased production of this marker by hepatic stellate cell as well as a decreased removal from circulation, which depends on the uptake by specific receptors in hepatic sinusoidal endothelial cells (40, 41). Higher HA levels and lower probability of virologic response could reflect dysfunction of endothelial sinusoidal cells that is present in patients with more advanced liver fibrosis, another independent predictor of virologic response. Our study has several limitations. First, the lack of a follow-up liver biopsy, which prevented us to directly assess the effect of treatment on liver fibrosis. Second, the short period of time that elapsed between baseline and follow-up evaluations. Since liver fibrosis decreases progressively after a sustained virologic response (42), the evaluation period of the study might have been too short to detect additional effects. Third, the proportion of patients with a biopsy size >20 mm was suboptimal. Finally, although this is a cohort study, ECM assays were performed on stored serum samples which were not available for all included patients.
In summary, this study of a large cohort of patients with CHC confirms that both indirect fibrosis tests and measurement of ECM serum markers, included in the ELF score, are accurate to predict the severity of fibrosis. ECM markers and the composite ELF score significantly decreased in sustained virologic responders but remained unchanged in non sustained responders, suggesting that these markers may be useful as a non-invasive means to assess the effects of antiviral therapy on hepatic fibrosis and fibrogenesis. The potential utility of the ELF test in this setting as compared with other commercially available patented markers would require extensive validation and a cost-effective analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 severe fibrosis, F≥ 3; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio; DOR, diagnostic odds ratio; OR, odds ratio. a 161 patients in whom ELF score was determined before and after antiviral therapy
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